Bitcoin has fallen 6.34% in 2025 and another 15.65% in 2026, trading near $73,850 as of November 10. To avoid its first-ever back-to-back annual losses in 18 years, Bitcoin must recover above its 2026 opening price of about $87,500 by year-end. The combined two-year loss of roughly 21% is mild compared to past crashes in 2018 and 2022, which saw declines over 60%. However, from its peak near $126,000 in October 2025, Bitcoin dropped more than 50% to below $58,000 during 2026, showing a sharper short-term decline. This unusual pattern breaks Bitcoin's historical trend of a positive year following a negative one, highlighting uncertainty in its near-term outlook.
Bitcoin's annual losses are on track for the first back-to-back streak in 18 years, with a combined two-year loss of about 21%. For readers following major cryptocurrencies, 27 out of 50 priced assets on Pluang rose today while 22 fell, as of Nov 12, 2026 05:22 WIB. Notable movers include UNI at Rp117.501 with a 3.70% decline, FIL at Rp13.938 gaining 2.97%, and XLM at Rp2.699 up 2.90%.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
